3 days Ago By ABMN Staff
Oppenheimer & Co. Inc. increased its holdings in shares of Viking Therapeutics, Inc.
( NASDAQ:VKTX – Free Report ) by 45.7% during the 2nd quarter, Holdings Channel.com reports.
The fund owned 71,313 shares of the biotechnology company’s stock after buying an additional 22,369 shares during the period. Oppenheimer & Co. Inc.
’s holdings in Viking Therapeutics were worth $3,780,000 as of its most recent filing with the Securities & Exchange Commission. Several other institutional investors and hedge funds have also recently bought and sold shares of VKTX. Massmutual Trust Co.
FSB ADV acquired a new stake in Viking Therapeutics during the first quarter worth about $25,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Viking Therapeutics in the 2nd quarter worth about $27,000.
Lindbrook Capital LLC grew its position in Viking Therapeutics by 370.7% in the 1st quarter. Lindbrook Capital LLC now owns 353 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 278 shares during the last quarter.
LifeSteps Financial Inc. bought a new position in Viking Therapeutics in the 1st quarter worth about $37,000. Finally, Spire Wealth Management bought a new position in Viking Therapeutics in the 1st quarter worth about $61,000.
Institutional investors and hedge funds own 76.03% of the company’s stock. Insider Buying and Selling In related news, CEO Brian Lian sold 115,859 shares of the firm’s stock in a transaction that occurred on Tuesday, July 30th.
The shares were sold at an average price of $57.58, for a total transaction of $6,671,161.22.
Following the completion of the sale, the chief executive officer now directly owns 2,354,927 shares in the company, valued at $135,596,696.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link .
In other Viking Therapeutics news, Director J Matthew Singleton sold 20,786 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.53, for a total value of $1,195,818.
58. Following the completion of the sale, the director now owns 9,500 shares in the company, valued at approximately $546,535. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link .
Also, CEO Brian Lian sold 115,859 shares of the stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $57.58, for a total transaction of $6,671,161.
22. Following the completion of the sale, the chief executive officer now owns 2,354,927 shares of the company’s stock, valued at approximately $135,596,696.66.
The disclosure for this sale can be found here . Over the last ninety days, insiders sold 290,241 shares of company stock worth $17,786,475. Corporate insiders own 4.
70% of the company’s stock. Viking Therapeutics Stock Performance Viking Therapeutics ( NASDAQ:VKTX – Get Free Report ) last issued its earnings results on Wednesday, July 24th. The biotechnology company reported ($0.
20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06.
During the same quarter in the prior year, the firm earned ($0.19) EPS. On average, sell-side analysts expect that Viking Therapeutics, Inc.
will post -0.99 EPS for the current fiscal year. Wall Street Analyst Weigh In Several research analysts have commented on VKTX shares.
Truist Financial restated a “buy” rating and issued a $120.00 target price on shares of Viking Therapeutics in a research report on Monday, June 17th. Maxim Group restated a “buy” rating and issued a $120.
00 target price on shares of Viking Therapeutics in a research report on Tuesday, June 4th. JPMorgan Chase & Co. started coverage on shares of Viking Therapeutics in a research report on Wednesday, September 11th.
They issued an “overweight” rating and a $80.00 target price for the company. Raymond James upped their target price on shares of Viking Therapeutics from $116.
00 to $118.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 25th. Finally, StockNews.
com upgraded shares of Viking Therapeutics to a “sell” rating in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Viking Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $108.
60. Read Our Latest Analysis on Viking Therapeutics Viking Therapeutics Company Profile ( Free Report ) Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Articles Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. ( NASDAQ:VKTX – Free Report ).
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
